{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"Number of participants with resolution of treatment-precipitating symptoms, defined as any resolution (from \"Yes\" at baseline to \"No\" at any postbaseline point onwards during study) of the indications for initiation of therapy in WM signs and symptoms evaluation.","groups":[{"description":"Zanubrutinib 160 mg orally twice daily with or without food until progressive disease or intolerable toxicity","id":"OG000","title":"Zanubrutinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Efficacy Analysis Set includes participants with confirmed Waldenström's macroglobulinemia based on central pathologic review among those who received at least one dose of study drug and with a baseline IgM (or M-protein) ≥ 5 g/L","reportingStatus":"POSTED","timeFrame":"Up to approximately 1 year and 9 months","title":"Number of Participants With Resolution of Treatment-precipitating Symptoms","type":"SECONDARY","unitOfMeasure":"Participants"}